Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-antigen specific tumor infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Tongji Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Neo-antigen specific tumor infiltrating lymphocytes (TILs) developed by Tongji Hospital is an autologous cell therapy designed for the treatment of advanced solid tumors. The therapeutic process involves isolating T cells from a patient's tumor tissue, identifying specific mutations (neo-antigens) unique to that patient's cancer through genomic sequencing, and selectively expanding TILs that demonstrate reactivity against these personalized neo-antigens. Following a lymphodepleting conditioning regimen typically consisting of cyclophosphamide and fludarabine, the enriched TIL population is re-infused into the patient. This treatment is often administered alongside aldesleukin (IL-2) to promote the survival, expansion, and anti-tumor activity of the infused cells. The goal of this precision immunotherapy is to leverage the patient's own immune system to specifically target and eliminate tumor cells while minimizing off-target toxicity.
- Other names
- Precision T cells specific to personalized neo-antigenAutologous neo-antigen specific TILsPersonalized Neo-antigen TILs
02
Targets
Patient-specific tumor neo-antigen peptides presented by Human Leukocyte Antigen (HLA)
Beyond the preview
Go deeper on Neo-antigen specific tumor infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-antigen specific tumor infiltrating lymphocytes.